Table 1. Overview of currently approved compounds.

Compound	Organization	Disease	Indication
Ipilimumab (1,2)	FDA, EMA	Cutaneous melanoma	Advanced unresectable melanoma
	FDA		Adjuvant treatment of patients with melanoma with involvement of regional lymph nodes, after complete resection including total lymphadenectomy
Nivolumab (1,2)	EMA, FDA	Cutaneous, melanoma	Advanced disease; unresectable or metastatic
	EMA	NSCLC	Advanced disease squamous histology
	FDA	Renal cell carcinoma, NSCLC	Advanced disease
			Advanced disease, non squamous and squamous histology
Pembrolizumab (1,2)	EMA, FDA	Melanoma	Advanced disease: unresectable or metastatic
	FDA	NSCLC	Metastatic, PD-L1 expressing, with disease progression on or after platinum-containing chemotherapy
Nivolumab + ipilimumab (1)	FDA	Melanoma	Advanced disease

FDA, Food and Drug Administration; EMA, European Medicines Agency; NSCLC, non-small cell lung cancer.